The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
Open accessAbstract
The clinical outcome of contralateral prophylactic mastectomy (CPM) in women with a BRCA1 or BRCA2 mutation and a personal history of invasive breast cancer is unknown. We identified a cohort of 148 female BRCA1 or BRCA2 mutation carriers (115 and 33, respectively) who previously were treated for unilateral invasive breast cancer stages I-IIIa. In all, 79 women underwent a CPM, while the other women remained under intensive surveillance. The mean follow-up was 3.5 years and started at the time of CPM or at the date of mutation testing, whichever came last, that is, on average 5 years after diagnosis of the first breast cancer. One woman developed an invasive contralateral primary breast cancer after CPM, whereas six were observed in the surveillance group (P<0.001). Contralateral prophylactic mastectomy reduced the risk of contralateral breast cancer by 91%, independent of the effect of bilateral prophylactic oophorectomy (BPO). At 5 years follow-up, overall survival was 94% for the CPM group vs 77% for the surveillance group (P=0.03), but this was unexpectedly mostly due to higher mortality related with first breast cancer and ovarian cancer in the surveillance group. After adjustment for BPO in a multivariate Cox analysis, the CPM effect on overall survival was no longer significant. Our data show that CPM markedly reduces the risk of contralateral breast cancer among BRCA1 or BRCA2 mutation carriers with a history of breast cancer. Longer follow-up is needed to study the impact of CPM on contralateral breast cancer-specific survival. The choice for CPM is highly correlated with that for BPO, while only BPO leads to a significant improvement in overall survival so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Self-citationRisk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
Unusual case of Smith‐Lemli‐Opitz syndrome “type II”
Seller, M. J., Russell, J., & Tint, G. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560305 · Cited by 585
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 543
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Prophylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., & Wallace, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub3 · Cited by 400
BRCA-associated breast cancer in young women.
Robson, M., Gilewski, T., Haas, B., Levin, D., Borgen, P., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., Lesser, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 302
McDonnell, S. K., Schaid, D. J., Myers, J. L., Grant, C. S., Donohue, J. H., Woods, J. E., Frost, M. H., Johnson, J. L., Sitta, D. L., Slezak, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3938 · Cited by 265
Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients
Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Hughes Halbert, C., DeMarco, T., Lawrence, W., Main, D., Finch, C., Magnant, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.086 · Cited by 251
Collaborating NSABP Investigators, Fisher, E. R., Sass, R., & Fisher, B. (1984) · Cancer · doi:10.1002/1097-0142(19840201)53:3+<712::aid-cncr2820531320>3.0.co;2-i · Cited by 250
Peralta, E. A., Ellenhorn, J. D. I., Wagman, L. D., Dagis, A., Andersen, J. S., & Chu, D. Z. J. (2000) · The American Journal of Surgery · doi:10.1016/s0002-9610(00)00505-5 · Cited by 198
Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2
Verhoog, L. C., Brekelmans, C. T. M., Seynaeve, C., Dahmen, G., van Geel, A. N., Bartels, C. C. M., Tilanus-Linthorst, M. M. A., Wagner, A., Devilee, P., Halley, D. J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3396 · Cited by 175
Prophylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., Wallace, J., Ezzo, J., & Dickersin, K. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub2 · Cited by 123
Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation
Klaren, H. M., Veer, L. J. V., van Leeuwen, F. E., & Rookus, M. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.941 · Cited by 78
Self-citationBilaterality in familial breast cancer patients
Anderson, D. E., & Badzioch, M. D. (1985) · Cancer · Cited by 71
Research works printed but not linked: 1
- Early Breast Cancer Trialists' Collaborative Group (2001) Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 4, CD000487.doi:10.1002/14651858.CD000487 · doi:10.1002/14651858.cd000487
Cited by
Prophylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., & Wallace, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub3 · Cited by 400
Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
Risk-reducing mastectomy for the prevention of primary breast cancer
Carbine, N. E., Lostumbo, L., Wallace, J., & Ko, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub4 · Cited by 266
Rosenberg, S. M., Tracy, M. S., Meyer, M. E., Sepucha, K., Gelber, S., Hirshfield-Bartek, J., Troyan, S., Morrow, M., Schapira, L., Come, S. E., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-6-201309170-00003 · Cited by 265
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Bianchi-Micheli, G., Cardoso, M.-J., Curigliano, G., Gelmon, K. A., Harbeck, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.284 · Cited by 254
Metadata
- Authors
- van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R., van Asperen, C. J., Rutgers, E. J. T., van‘t Veer, L. J., & Tollenaar, R. A. E. M.
- Venue
- British Journal of Cancer
- Published
- 2005-07-19
- Volume
- 93
- Issue
- 3
- Pages
- 287-292
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2062367399
- Cited by
- 291
- References
- 19
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.